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Abstract
Background: Differentiation of F9 embryonal carcinoma (EC) cells into parietal endoderm (PE) provides a tractable
model system for studying molecular events during early and inaccessible stages of murine development. PE
formation is accompanied by extensive changes in gene expression both in vivo and in culture. One of the most
dramatic is the ~10-fold decrease in transcriptional output by RNA polymerase (pol) III. This has been attributed to
changes in activity of TFIIIB, a factor that is necessary and sufficient to recruit pol III to promoters. The goal of this
study was to identify molecular changes that can account for the low activity of TFIIIB following F9 cell
differentiation.
Results: Three essential subunits of TFIIIB decrease in abundance as F9 cells differentiate; these are Brf1 and Bdp1,
which are pol III-specific, and TBP, which is also used by pols I and II. The decreased levels of Brf1 and Bdp1
proteins can be explained by reduced expression of the corresponding mRNAs. However, this is not the case for
TBP, which is regulated post-transcriptionally. In proliferating cells, pol III transcription is stimulated by the proto-
oncogene product c-Myc and the mitogen-activated protein kinase Erk, both of which bind to TFIIIB. However, c-
Myc levels fall during differentiation and Erk becomes inactive through dephosphorylation. The diminished
abundance of TFIIIB is therefore likely to be compounded by changes to these positive regulators that are required
for its full activity. In addition, PE cells have elevated levels of the retinoblastoma protein RB, which is known to
bind and repress TFIIIB.
Conclusion: The low activity of TFIIIB in PE can be attributed to a combination of changes, any one of which
could be sufficient to inhibit pol III transcription. Declining levels of essential TFIIIB subunits and of activators that
are required for maximal TFIIIB activity are accompanied by an increase in a potent repressor of TFIIIB. These events
provide fail-safe guarantees to ensure that pol III output is appropriate to the diminished metabolic requirements
of terminally differentiated cells.
Background
Differentiation of F9 embryonal carcinoma (EC) cells
into parietal endoderm (PE) is accompanied by dramatic
changes in gene expression. Amongst these are a
marked decrease in transcription of tRNA and 5S rRNA
genes by pol III, which reflects a reduced requirement
for biosynthesis as the differentiating cells stop growing
and dividing [1]. Biochemical reconstitution experiments
suggested that this change is caused by a specific
decrease in activity of the essential pol III transcription
factor TFIIIB [1,2]. In support of this, western blot ana-
lysis revealed that PE cells express markedly reduced
levels of Brf1, a subunit of TFIIIB that binds pol III and
brings it to its targets genes [2]. F9 cell differentiation
also involves a decrease in the level of the TATA-bind-
ing protein TBP, which is another essential subunit of
TFIIIB [2,3]. However, the conclusion that pol III tran-
scription is regulated under these circumstances through
changes in TFIIIB proved to be controversial. Meissner
and colleagues argued that TFIIIB activity is unchanged
during differentiation and that transcriptional control
reflects other mechanisms [4,5]. They subsequently
implcated Bdp1, a third essential subunit of TFIIIB [6].
Here we compare directly the behaviour of the TFIIIB
components Brf1, TBP and Bdp1, which had not been
done in any of the previous studies. We confirm that
each is down-regulated when F9 cells differentiate.
Whereas TBP is subject to post-transcriptional control,
the fall in Brf1 and Bdp1 levels reflects changes in the
corresponding mRNAs. We show that transcriptional
repression occurs even if Brf1 expression is maintained
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lators that are known to act directly on TFIIIB.
Results
Raising Brf1 expression in F9 cells does not stimulate
tRNA expression or proliferation
To test the role of Brf1 levels in dictating pol III output
during differentiation, we examined whether it is possi-
ble to construct an F9 cell derivative in which Brf1
expression is maintained in PE cells. To this end, a
pcDNA3 expression vector containing human Brf1
cDNA was introduced by stable transfection to create a
cell line that we refer to as Brf1.F9. Since this cDNA is
transcribed from a constitutive CMV promoter, it
should not be subject to the same regulatory influences
that act on the endogenous gene. Indeed, RT-PCR ana-
lysis confirmed that expression from the CMV promoter
is undiminished following differentiation (data not
shown). Quantitation of western blots revealed that the
total level of Brf1 in undifferentiated cells was raised by
approximately four-fold in Brf1.F9 cells, relative to
untransfected cells or control cells, referred to as Vec.
F9, that carry empty pcDNA3 vector (Fig. 1).
An increase in Brf1 expression was found to stimulate
proliferation of immortalized mouse embryonic fibro-
blasts (MEFs), IMR90 human diploid fibroblasts and
CHO cells [7]. However, the Brf1.F9 cells proliferate at
the same rate as matched Vec.F9 control cells, both
before and after differentiation (Fig. 2a and 2b). In the
case of MEFs, the proliferative response to Brf1 eleva-
tion can be mimicked by overexpressing a key Brf1 tar-
get, the tRNAi
Met that is required for translation
initiation [7]. Whereas tRNAi
Met levels increase in
response to Brf1 induction in MEFs [7], Brf1.F9 cells
express no more tRNAi
Met than Vec.F9 control cells,
after expression was normalised to the mRNA encoding
acidic ribosomal phosphoprotein P0 (ARPP P0) (Fig. 2c).
As positive control, we confirmed that Brf1 mRNA is
elevated in the Brf1.F9 cells. Another tRNA that can be
induced in a variety of cell types by raising Brf1 levels is
tRNA
Leu [7-9]. Nevertheless, as with tRNAi
Met,c o m p a r -
able levels of tRNA
Leu are detected in Brf1.F9 and Vec.
F9 cells. Although we have only tested two examples,
these data suggest that Brf1 is not limiting for tRNA
expression in F9 cells. This contrasts with MEFs, HeLa,
Rat1a and CHO cells [7-9]. Clearly, a failure to raise
expression of key genes offers a ready explanation for
the lack of a proliferative response.
Constant Brf1 expression does not prevent pol III
transcription from decreasing when F9 cells differentiate
Although apparently not limiting, the exogenous Brf1 in
our cell lines allowed us to determine if down-regulation
of pol III transcription during F9 cell differentiation is
dependent on the decrease in Brf1 expression that nor-
mally accompanies this transition [2]. To facilitate
detection, a HA tag was included at the N-terminus of
the exogenous Brf1 in Brf1.F9 cells. Immunoblotting
with antibody against this tag detected not only HA-
Brf1, but also a smaller protein of unknown identity,
that appears during differentiation; this protein is not
derived from the vector, as it is also detected in untrans-
fected cells (Fig. 3a, lanes 1 and 2). Nevertheless, it is
clear that HA-Brf1 levels are maintained in the Brf1.F9
cells after differentiation into PE (Fig. 3a, lanes 3 and 4).
Despite this, tRNA gene transcriptional activity was
decreased by ~10-fold in extracts of fully differentiated
Brf1.F9 cells that continued to express the exogenous
H A - B r f 1( F i g s .3 ba n d3 c ) .T h i sc h a n g ei sn o ts i g n i f i -
cantly different from the decrease seen in untransfected
F9 cells (P = 0.86). These data suggest that additional
changes to the pol III machinery also occur when F9
cells differentiate.
F9 cell differentiation is accompanied by specific changes
in expression of all three TFIIIB subunits
Western blot analysis demonstrated that not only Brf1,
but also TBP and Bdp1 protein levels are markedly
lower in PE cell extracts relative to undifferentiated EC
cell extracts (Fig. 4a). In contrast to these decreases in
the three TFIIIB subunits, the PE samples show a large
increase in expression of laminin B1, an established
marker of differentiation (Fig. 4b). These changes are
specific, since levels of actin and TFIIIC110 (Fig. 4c)
remain relatively constant when the EC and PE cell
extracts are compared.
T h ef a c tt h a tH A - B r f 1p r o t e i ni se x p r e s s e da t
unchanged levels in PE cells indicates that the observed
decrease in endogenous Brf1 is unlikely to be caused by
Figure 1 Expression of exogenous Brf1 in F9 cell stable
transfectants. Western blot of whole cell extract (20 μg) from
untransfected F9 cells (lane 1), Brf1.F9 cells (lane 2) and vec.F9 cells
(lane 3) probed with antibodies 128 against Brf1 and C-11 against
actin, as indicated.
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that transcription of the endogenous Brf1 gene may be
regulated, a mechanism evaded by the CMV promoter
that we used to express HA-Brf1. This hypothesis was
supported by RT-PCR analysis, which showed that levels
of endogenous Brf1 mRNA are lower following differen-
tiation (Fig. 4d). Quantification of four experiments
revealed that Brf1 is expressed in PE cells at ~62% of
the level observed in undifferentiated EC cells, after nor-
malization to ARPP P0 mRNA. Similarly, the level of
Bdp1 mRNA in PE cells is ~46% of that in EC cells, on
average. In contrast, TBP mRNA levels are ~72% higher
in PE cells relative to EC cells. We conclude that Brf1
and Bdp1 expression is regulated at the mRNA level in
differentiating F9 cells. The decrease in Brf1 mRNA
expression seen by RT-PCR is less than the decrease
seen in Brf1 protein by western immunoblotting. This
apparent discrepancy might be explained if Brf1 protein
levels respond in a non-linear fashion to the modest
decrease in mRNA. In contrast to Brf1 and Bdp1, levels
of TBP protein are dictated through post-transcriptional
control, as shown by Perletti et al., who demonstrated
the selective proteolysis of TBP when F9 cells differenti-
ate [3].
Both activators and repressors of TFIIIB are regulated
during F9 cell differentiation
The activity of TFIIIB in mammals is subject to regula-
tion by a variety of accessory proteins with which it is
stably associated [10-12]. These include p53 and the RB
family, which inhibit TFIIIB, as well as c-Myc and Erk,
which activate TFIIIB. Since each of these regulators
can have a profound influence on TFIIIB function, we
investigated whether they are also affected by F9 cell
differentiation.
Several groups have shown independently that RB can
bind and repress TFIIIB [13-17]. The interaction is
regulated by cyclin-dependent kinases [16,18]. It results
Figure 2 Stable expression of Brf1 in F9 cells does not stimulate proliferation. a, b Proliferation curves showing numbers of viable Brf1.F9
(blue) and vec.F9 (red) cells, as determined by trypan blue staining, each day after plating 10
4 undifferentiated EC cells (a) or differentiated PE
cells (b). Counts were taken in triplicate and the results are presented as averages of three independent experiments +/- standard deviation. c
RT-PCR analysis to compare expression of tRNAi
Met and tRNA
Leu, and mRNAs encoding Brf1 and ARPP P0 in vec.F9 and Brf1.F9 cells, as indicated.
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Page 3 of 8Figure 3 Stable expression of Brf1 in F9 cells does not prevent down-regulation of tRNA gene transcription following differentiation.a
Western blot of whole cell extract (50 μg) from untransfected F9 cells (lanes 1 and 2) and Brf1.F9 cells (lanes 3 and 4) before (EC) or after (PE)
differentiation. Blots were probed with antibodies F-7 against HA and C-11 against actin, as indicated. b Quantitative comparison of tRNA
Leu gene
transcription in vitro using extracts (20 μg) of Brf1.F9 and untransfected F9 cells before (EC) and after (PE) differentiation. Graph shows mean from
three independent experiments +/- standard deviation. c Representative example of one of the transcription assays quantified in Fig. 3b.
Figure 4 Differentiation of F9 EC cells into PE is accompanied by specific decreases in expression of Brf1, Bdp1 and TBP proteins, as
well as Brf1 and Bdp1 mRNAs. a Western blot of whole cell extract (50 μg) from untransfected F9 cells before (EC) or after (PE) differentiation
and probed with antibodies against Brf1, Bdp1, TBP and actin, as indicated. b Western blot of whole cell extract (20 μg) from untransfected F9
cells before (EC) or after (PE) differentiation and probed with antibodies against laminin B1 and actin, as indicated. c Western blot of whole cell
extract (50 μg) from untransfected F9 cells before (EC) or after (PE) differentiation and probed with antibodies against TFIIIC110 and actin, as
indicated. d RT-PCR analysis to compare expression of mRNAs encoding Brf1, Bdp1, TBP and ARPP P0 in undifferentiated (EC) and differentiated
(PE) F9 cells, as indicated.
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the ability of TFIIIB to bind to pol III and TFIIIC [19].
Western blotting revealed a substantial increase in RB
expression in PE cells (Fig. 5a). TFIIIB is also bound
and inhibited by the RB-related pocket proteins p107
and p130 [20], but the levels of these change little
between EC and PE cells (Fig. 5a). We also detected
minimal change in p53 abundance during F9 cell differ-
entiation (data not shown). Changes in the post-transla-
tional modification state of p53 remain a possibility, but
we have not investigated these, as it is currently
unknown how they may influence the ability of p53 to
regulate TFIIIB.
Pol III transcription can be stimulated by the proto-
oncogene product c-Myc [9,10,21,22]. Recruitment of
TFIIIB to target genes is facilitated by c-Myc, an effect
that involves the cofactor GCN5 and localised acetyla-
tion of histone H3 [22]. We found that expression of
c-Myc decreases dramatically when F9 cells differentiate
(Fig. 5B), as previously reported [23,24]. In contrast, lit-
tle or no change was detected in expression of Max, the
dimerisation partner of c-Myc. A second potent activa-
tor of TFIIIB is the MAP kinase Erk, which binds and
phosphorylates Brf1 [25]. Although the total concentra-
tion of Erk protein is relatively constant, its active phos-
phorylated form is much less prevalent in PE cells (Fig.
5C). Thus, the TFIIIB remaining in these differentiated
cells is likely to be deprived of two key regulators that
are required for its full activity.
Discussion
Experiments with crude phosphocellulose fractions pro-
vided the first indication that pol III transcription is
down-regulated during F9 cell differentiation through
inactivation of TFIIIB [1]. At the time, the composition
of TFIIIB had not been determined and so molecular
reagents were unavailable. The possibility therefore
remained that the biochemical activity assays were in
fact responding to some alternative factor, present in
t h es a m ec r u d ef r a c t i o n s .O n c et h es u b u n i t so fT F I I I B
were identified, regulatory studies could be conducted
with a great deal more certainty. The use of specific
antibodies allowed demonstration that differentiation
of F9 cells is accompanied by a marked decrease in
the levels of TBP and Brf1 [2]. This down-regulation
of TBP has also been reported independently [3].
Nevertheless, another study suggested that although
TFIIIB may become limiting and contribute to the
down-regulation of transcription, it cannot account for
it [5]. The authors proposed that the key regulatory
event that dictates pol III output during differentiation
is loss of an activity that they referred to as TFIIIC1 [5].
However, their subsequent analysis revealed that Bdp1
was present in the TFIIIC1 fractions and required for
their activity [6]. Indeed, recombinant Bdp1 could sub-
s t i t u t ef o rt h eT F I I I C 1f r a c t i ons in reconstituting tran-
scription [6]. Western blotting showed a decrease in
Bdp1 expression in differentiated F9 cells [6], a result
that we have confirmed here with an alternative anti-
body and by RT-PCR. Both groups’ data therefore sup-
port the original model that down-regulation of TFIIIB
is responsible for the substantial decrease in pol III
transcription that occurs when F9 cells differentiate.
Given that the model was based on the use of extremely
crude fractions, it is perhaps surprising that it has
turned out to be correct.
For most pol III-transcribed genes, including those
encoding tRNA and 5S rRNA, the essential components
of TFIIIB are TBP, Bdp1 and Brf1 [26]. However, a sub-
set of pol III-dependent genes use a form of TFIIIB in
which Brf1 is replaced by its homologue Brf2; these all
have upstream (type 3) promoters and include the genes
encoding U6, 7SK and Y RNAs. We have not investi-
gated Brf2 in this study.
Figure 5 Differentiation of F9 EC cells into PE is accompanied by specific changes in regulators of TFIIIB activity.aW e s t e r nb l o to f
whole cell extract (20 μg) of undifferentiated (EC) and differentiated (PE) F9 cells using antibodies against RB, p107, p130 and TFIIB, as indicated.
b Western blot of whole cell extract (20 μg) of undifferentiated (EC) and differentiated (PE) F9 cells using antibodies against c-Myc, Max, TFIIB
and actin, as indicated. c Western blot of whole cell extract (20 μg) of undifferentiated (EC) and differentiated (PE) F9 cells using antibodies
against total Erk and active (phosphorylated) Erk, as well as TFIIB, as indicated.
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tors during differentiation are a feature of other tran-
scription systems besides pol III. For example, levels of
TAFI48 and TAFI95 decrease when F9 cells differentiate,
causing a fall in pol I transcription [27]. The same pair
of pol I-specific TAFs are down-regulated during differ-
entiation of B cells into plasma cells [28]. These TAFs
are part of the SL1 complex, which is also inactivated
when U937 promyelocytic cells differentiate [29]. How-
ever, the loss of SL1 activity in U937 cells is not due to
changes in the abundance of its constituent TAFs or
TBP [29]. The molecular basis of this has not been
established, but might reflect loss of c-Myc, which has
been shown to bind and activate SL1 [30]. Down-regu-
lated expression of some pol II-specific TAFs has also
been observed during differentiation of F9 cells and
C2C12 myoblasts [3,31]. Changes in TAF levels seem
therefore to be used in various systems to re-pro-
gramme gene transcription as cells differentiate.
Expression of the Bdp1 gene is very sensitive to TBP
levels, whereas the Brf1 gene is less responsive [32]. The
decreased Bdp1 mRNA in F9 PE cells may therefore be
a consequence of TBP down-regulation. In contrast, an
Erk inhibitor suppresses expression of Brf1, but not
Bdp1 [33]. Furthermore, Brf1 expression is stimulated
by c-Myc [34]. It is therefore possible that the decrease
in Brf1 levels following F9 cell differentiation is caused
by the observed regulation of c-Myc and/or Erk. As
TBP is down-regulated by selective proteolysis in differ-
entiating F9 cells [3], we wondered if the same applies
to Brf1. However, our data argue strongly against this,
since Brf1 protein levels are maintained when the gene
is expressed from a constitutive promoter. Regulated
proteolytic turnover has not been excluded for Bdp1,
but the decrease detected in its mRNA may be sufficient
to account for the down-regulation of this TAF.
The fact that forced expression of Brf1 does not
restore transcription in PE cells does not mean that Brf1
control is irrelevant in this system. We interpret it as
being a reflection of regulatory redundancy, where more
than one control mechanism can be sufficient to achieve
a phenotypic end point. Indeed, we do not believe that
pol III transcription could be restored by reversing any
one of the changes that we have documented. Although
we have only tested this directly in the case of Brf1, we
do not feel it is worth attempting further, as the pro-
spects of success seem remote. Restoring TBP or Bdp1
levels in PE cells is unlikely to have much impact if Brf1
levels become limiting. Co-expressing all three subunits
would be difficult to achieve and still would be unlikely
to be effective, given the high levels of RB, which is
known to bind and repress TFIIIB [13-17]. Depletion of
c-Myc is sufficient to inhibit pol III transcription
[10,21,30,33]. If c-Myc were introduced into PE cells, its
Figure 6 Model of changes to the pol III transcription machinery that accompany differentiation of F9 EC cells into PE. In EC cells, tRNA
genes are transcribed very actively, reflecting the availability of TFIIIB, c-Myc and activated Erk. Differentiation is accompanied by decreased levels
of TFIIIB and c-Myc, as well as inactivation of Erk and induction of RB. PE cells contain relatively little TFIIIB, which is deprived of activators and
liable to inhibition by RB; as a consequence, transcription of tRNA genes is severely restricted.
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sor proteins, which are induced during differentiation
[35]. Furthermore, Erk inhibition is sufficient to sup-
press pol III transcription [25,33] and would not be
reversed by overexpressing this kinase, as its inactivation
in PE cells reflects its dephosphorylation, rather than
loss of Erk itself. These considerations have convinced
us that attempts to restore TFIIIB activity in PE cells
are unlikely to be successful.
Conclusion
In summary, differentiation of F9 EC cells is accompa-
nied by several specific and drastic changes to TFIIIB
and its associated regulators (Fig. 6). The abundance of
TBP, Brf1 and Bdp1 decreases markedly. This reflects a
fall in the expression of mRNAs encoding Brf1 and
Bdp1, whereas TBP is regulated post-transcriptionally.
The TFIIIB remaining in PE cells is deprived of c-Myc
and active Erk, both of which are important for its opti-
mal function. In addition, it must contend with highly-
elevated levels of its inhibitor RB. These combined
changes are more than sufficient to explain the low
rates of pol III transcription that are a feature of this
differentiated cell type.
Methods
Cell culture and stable transfection
F9 EC cells were cultured in Dulbecco’s modified eagle
medium containing 10% foetal bovine serum, 1 mM
L-glutamine, 100 U/ml penicillin and 100 μg/ml strepto-
mycin (all from Sigma). Full differentiation was achieved
after 6-7 days by supplementing the medium with 0.1
μM retinoic acid, 1 mM dibutyryl cyclic AMP and 0.1
mM 3-isobutyl-1-methylxanthine (all from Sigma). G418
sulphate (PAA laboratories) was included at a concen-
tration of 500 μg/ml in the medium for stably trans-
fected cells.
Brf1.F9 and Vec.F9 lines were made by transfecting F9
EC cells with pcDNA3.1-HA-HsBrf1 [19] or pcDNA3.1-
HA vector (Invitrogen), respectively, using Superfect
(Qiagen). After 24 hrs, medium was supplemented with
G418 sulphate (500 μg/ml). G418-resistant clones were
isolated after four weeks and screened for expression of
HA-Brf1 by western blotting with anti-HA antibody F-7
(Santa Cruz Biotechnology Inc).
RNA and protein expression assays
Transcript expression was assayed by RT-PCR, using pub-
lished procedures for RNA extraction and reverse tran-
scription [36]. Primers and PCR parameters have been
described for Brf1 mRNA [37], Bdp1 and TBP mRNA
[38], ARPP P0 mRNA [39], tRNA
Leu [40] and tRNAi
Met
[7]. In vitro transcription assays were conducted with
whole cell extracts as previously described [41].
Protein expression was assayed by western blotting of
whole cell extracts, as previously described [41]. Antibo-
dies used were 128 against Brf1 [42], 2663 against Bdp1
[8], 4286 against TFIIIC110 [39], 9102 against Erk and
9106 against activated Erk (both from Cell Signalling
Technology), and the following antibodies from Santa
Cruz Biotechnology Inc: 58C9 against TBP, IF8 against
RB, C-18 against p107, C-20 against p130, N-262 against
c-Myc, C-17 against Max, C-18 against TFIIB, A-1
against laminin B1, C-11 against actin and F-7 against
the HA tag. Quantification was performed using the
TotalLab software from Nonlinear Dynamics, Newcastle,
UK and normalized against actin.
Abbreviations
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